

17. The derivative of claim 15, wherein said derivative has at least 95% amino acid identity to said GLP-1 (7-37).


18. A derivative of glucagon-like peptide-1 (7-37), (GLP-1 (7-37)), wherein the amino acid sequence of said derivative has the same number of amino acids as said GLP-1 (7-37), and an insulintropic activity that exceeds the insulintropic activity of GLP-1 (1-37) and GLP-1 (1-36), and wherein the amino acid sequence of said derivative is that of GLP-1 (7-37) except that an amino acid residue has been substituted with a different amino acid residue.

19. The derivative of claim 18, wherein a hydrophobic amino acid residue of GLP-1 (7-37) has been substituted with a different hydrophobic amino acid residue.

20. The derivative of claim 18, wherein a basic amino acid residue of GLP-1 (7-37) has been substituted with a different basic amino acid residue.

21. The derivative of claim 18, wherein an aromatic amino acid residue of GLP-1 (7-37) has been substituted with a different aromatic amino acid residue.

22. A derivative of glucagon-like peptide-1 (7-37), (GLP-1 (7-37)), said derivative having the formula:



- wherein  $\text{R}^1$  is OH, OM, or  $-\text{N R}^2 \text{R}^3$ ;

B<sup>2</sup>  
Cont

- M is a pharmaceutically acceptable cation or a lower branched or unbranched alkyl group;
  - R<sup>2</sup> and R<sup>3</sup> are the same or different and selected from the group consisting of hydrogen and a lower branched or unbranched alkyl group;
  - X is a derivative of glucagon-like peptide-1 (7-37), (GLP-1 (7-37)), wherein the amino acid sequence of said derivative has the same number of amino acids as said GLP-1 (7-37), and has at least 80% amino acid identity to said GLP-1 (7-37);
  - NH<sub>2</sub> is the amine group of the amino terminus of X;
  - CO is the carbonyl group of the carboxy terminus of X;
- (2) the acid addition salts of (1);
  - (3) the amino or carboxyl protected form of (1);
  - (4) a pharmaceutically acceptable carboxylate salt of said peptide;
  - (5) a pharmaceutically acceptable lower alkyl ester of said peptide; or
  - (6) a pharmaceutically acceptable amide of said peptide;


wherein said derivative has an insulintropic activity that exceeds the insulintropic activity of GLP-1 (1-37) and GLP-1 (1-36).

B<sup>2</sup>  
Cont.

23. The derivative of claim 22, wherein said derivative has at least 90% amino acid identity to said GLP-1 (7-37).

24. The derivative of claim 22, wherein said derivative has at least 95% amino acid identity to said GLP-1 (7-37).

25. A derivative of glucagon-like peptide-1 (7-37), (GLP-1 (7-37)), said derivative having the formula:



- wherein  $\text{R}^1$  is OH, OM, or  $-\text{N R}^2 \text{R}^3$ ;

- M is a pharmaceutically acceptable cation or a lower branched or unbranched alkyl group;

-  $\text{R}^2$  and  $\text{R}^3$  are the same or different and selected from the group consisting of hydrogen and a lower branched or unbranched alkyl group;

- X is a derivative of glucagon-like peptide-1 (7-37), (GLP-1 (7-37)), wherein the amino acid sequence of said derivative is that of GLP-1 (7-37) except that an amino acid residue has been substituted with a different amino acid residue;

-  $\text{NH}_2$  is the amine group of the amino terminus of X;

- CO is the carbonyl group of the carboxy terminus of X;

(2) the acid addition salts of (1);

32  
cont.

- (3) the amino or carboxyl protected form of (1);
- (4) a pharmaceutically acceptable carboxylate salt of said peptide;
- (5) a pharmaceutically acceptable lower alkyl ester of said peptide; or
- (6) a pharmaceutically acceptable amide of said peptide;

wherein said derivative has an insulintropic activity that exceeds the insulintropic activity of GLP-1 (1-37) and GLP-1 (1-36).

26. The derivative of claim 25, wherein a hydrophobic amino acid residue of GLP-1 (7-37) has been substituted with a different hydrophobic amino acid residue.

27. The derivative of claim 25, wherein a basic amino acid residue of GLP-1 (7-37) has been substituted with a different basic amino acid residue.

28. The derivative of claim 25, wherein an aromatic amino acid residue of GLP-1 (7-37) has been substituted with a different aromatic amino acid residue.

B2  
Cnt

29. A method for treating type II diabetes mellitus in a patient in need of such treatment, said method comprising providing the derivative of any one of claims 15-28 to said patient in an amount sufficient to treat said diabetes. --

---

**Remarks**

None of the amendments add new matter. Claims 15- 29 are pending.